Concept Life Sciences providing ‘fully integrated offering’ in the early development space

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)

Related tags: API, Concept Life Sciences, Preclinical services, analytical

The drug discovery, development, and analytical service provider has opened a new facility in Sandwich, UK to support the development and manufacturing of APIs – a market expected to top $270bn by 2026.

The new clinical and niche commercial facility will add current good manufacturing practice (cGMP) active pharmaceutical ingredient (API) synthesis from gram-scale to multi-kilo capability, said Dr. Paul Doyle, chief scientific officer.

The facility and offering complements the company’s other sites, which provide analytical, stability, material science, and formulation services.

“Ultimately this results in a fully integrated offering in the early development space to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients,”​ Doyle told us.

The company’s business has been driven by customer demand in what Doyle described as a growing marketplace – some forecasts suggest the API market will be worth more than $274.9bn by 2026, he said.

“Concept Life Sciences is seeing the highest demand from our customers when they are transitioning from late lead optimization through to preclinical and clinical development,”​ Doyle added.

“Adding cGMP API capabilities allows a seamless transition from gram-scale chemistry through to non-GMP and GMP production,”​ he said, “thus allowing us to support customers moving into these different phases of development.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us


View more